Small molecule · developed by UroGen Pharma
UGN-103 is a sustained-release reverse thermal hydrogel formulation of mitomycin C, given by intravesical instillation. The liquid forms a gel that conforms to the bladder wall, where mitomycin C alkylates DNA and produces interstrand cross-links that inhibit DNA synthesis. It is studied in bladder cancer and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06331299 | Phase 3 | Bladder Cancer | Completed | URGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.
See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
URGN catalysts and pipeline →